| 摘要 |
An improved method for orally administering buspirone to a human subject wherein the bioavailability of buspirone is increased and its elimination, metabolite formation, and variability of these pharmacokinetic parameters is decreased, the improvement comprises the concurrent administration of a sufficient amount of nefazodone to effect these pharmacokinetic changes for orally administered buspirone. |
